Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines

Journal of Neuroimmunology

Volumn 148, Issue 1-2, 2004, Pages 162-171

  Reale, Marcella ^a   Iarlori, Carla ^a   Gambi, Francesco ^a   Feliciani, Claudio ^a   Salone, Anatolia ^a   Toma, Lucia ^a   DeLuca, Giovanna ^a   Salvatore, Mirella ^b   Conti, Pio ^a   Gambi, Domenico ^a  

^a University UD'A   (Italy)

^b Faculty of Economics   (Italy)

Author keywords

Alzheimer's disease; IL 1 ; IL 4; IL 6; PBMC; TNF

Indexed keywords

CHOLINESTERASE INHIBITOR; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE; MALE; NEUROMODULATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 10744222732     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2003.11.003     Document Type: Article

References (47)

1. Abbas N., Bednar I., Mix E., Marie S., Paterson D., Ljungberg A., Morris C. Up-regulation of the inflammatory cytokines IFN-g and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APPSWE transgenic mice. J. Neuroimmunol. 126:2002;50-57.
2. Benveniste E.N. Inflammatory cytokines within the central nervous system: source, function, and mechanism of action. Am. J. Physiol. 363:1992;C1-C16.
3. Bruunsgaard H., Pedersen B.K. Age-related inflammatory cytokines and disease. Immunol. Allergy Clin. North Am. 23:2003;15-39.
4. Bruunsgaard H., Andersen-Ranberg K., Jeune B., Pedersen A.N., Skinhoj P., Pedersen B.K. A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J. Gerontol., Ser. A, Biol. Sci. Med. Sci. 54:1999;M357-M364.
5. Chao C.C., Molitor T.W., Hu S. Neuroprotective role of IL-4 against activated microglia. J. Immunol. 151:1993;1473-1481.
6. Chao C.C., Hu S., Ehrlich L., Peterson P.K. Interleukin-1 and tumour necrosis factor-alpha synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-D-aspartate receptors. Brain Behav. Immun. 9:1995;355-365.
7. Conti P., Dempsey R.A. Interleukin-4 and interleukin-1 receptor antagonist down-regulate interleukin-1 and tumour necrosis factor (TNF) generation in macrophages. Int. J. Immunopathol. Pharmacol. 2:1990;I-II.
8. Del Bo R., Angeretti N., Lucca E., De Simoni M.G., Forloni G. Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and β-amyloid production in cultures. Neurosci. Lett. 188:1995;70-74.
9. De Luca G., Lugaresi A., Iarlori C., Marzoli F., Uncini A., Gambi D. Interferon beta normalizes suppressor cell function in dysimmune neuropathies. J. Neuroimmunol. 82:1998;1-4.
10. Dinarello C.A. Role of pro- and anti-inflammatory cytokines during inflammation: experimental and clinical findings. J. Biol. Regul. Homeost. Agents. 11:1997;91-103.
11. Engelborghs S., De Brabander M., De Cree J., D'Hooge R., Geerts H., Verhaegen H., De Deyn P.P. Unchanged levels of interleukins, neopterin, interferon-gamma and tumour necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type. Neurochem. Int. 34:1999;523-530.
12. Fillit H., Ding W., Buee L., Kalman J., Altstiel L., Lawlor B., Wolf-Klein G. Elevated circulating tumour necrosis factor levels in Alzheimer's disease. Neurosci. Lett. 129:1991;318-320.
13. Folstein M.F., Folstein S.E., McHug P.R. Mini-mental state: a practical methods for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12:1975;189-198.
14. Gerli R., Monti D., Bistoni O., Mazzone A.M., Peri G., Cossarizza A., Di Gioacchino M., Cesarotti M.E., Doni A., Mantovani A., Franceschi C., Paganelli R. Chemokines, sTNF-Rs and sCD30 serum levels in healthy aged people and centenarians. Mech. Ageing Dev. 121:2000;37-46.
15. Giacobini E. Is anti-cholinesterase therapy of Alzheimer's disease delaying progression? Aging. 13:2001;247-254.
16. Goldgaber D., Harris H.W., Hla T., Maciag T., Donnelly R.J., Jacobsen J.S., Vitek M.P., Gajdusek D.C. Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 86:1989;7606-7610.
17. Griffin W.S.T., Sheng J.G., Roberts G.W., Mrak R.E. Interleukin-1 expression in different plaque types in AD: significance in plaque evolution. J. Neuropathol. Exp. Neurol. 54:1995;276-281.
18. Hart P.H., Vitti G.F., Buegess D.R., Whitty G.A., Piccoli D.S., Hamilton J.A. Potential anti-inflammatory effects of interleukin 4: suppression of human monocyte tumour necrosis factor alpha, interleukin 1 and prostaglandin E2. Proc. Natl. Acad. Sci. U. S. A. 86:1989;3803-3807.
19. Huell M., Strauss S., Volk B., Berger M., Bauer J. Interleukin-6 is present in early stage of plaque formation and is restricted to the brains of Alzheimer's disease patients. Acta Neuropathol. (Berl.). 89:1995;544-551.
20. Iarlori C., Reale M., Lugaresi A., De Luca G., Bonanni L., Di Iorio A., Feliciani C., Conti P., Gambi D. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b. J. Neuroimmunol. 107:2000;100-107.
21. Iarlori C., Reale M., De Luca G., Di Iorio A., Feliciani C., Tulli A., Conti P., Gambi D., Lugaresi A. Interferon beta-1β, modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis. J. Neuroimmunol. 123:2002;170-179.
22. Kalman J., Juhasz A., Laird G., Dickens P., Jardanhazy T., Rimanoczy Boncz I., Parry-Jones W.L., Janka Z. Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and Alzheimer's disease. Acta Neurol. Scand. 96:1997;236-240.
23. Kawashima K., Fujii T. The lymphocytic cholinergic system and its biological function. Life Sci. 72:2003;2101-2109.
24. Lanzrein A.S., Johnston C.M., Perry V.H., Jobst K.A., King E.M., Smith A.D. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumour necrosis factor-alpha, the soluble tumour necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis. Assoc. Disord. 12:1998;215-227.
25. Ledeboer A., Breve J.J., Poole S., Tilders F.J., Van Dam A.M. Interleukin-10, interleukin-4, and transforming growth factor-beta differentially regulate lipopolysaccharide-induced production of pro-inflammatory cytokines and nitric oxide in co-cultures of rat astroglial and microglial cells. Glia. 30:2000;134-142.
26. Lee J.D., Rhoades K., Economou J.S. Interleukin-4 inhibits the expression of tumour necrosis factors alpha and beta, interleukins-1 beta and -6 and interferon-gamma. Immunol. Cell Biol. 73:1995;57-61.
27. Licastro F., Pedrini S., Caputo L., Annoni G., Davis L.J., Ferri C., Casadei V., Grimaldi L.M. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J. Neuroimmunol. 103:2000;97-102.
28. Lombardi V.R.M., Garcia M., Rey L., Cacabelos R. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy an Alzheimer disease (AD) individuals. J. Neuroimmunol. 97:1999;163-171.
29. Maat-Schieman M.L., van Duinen S.G., Rozemuller A.J., Haan J., Ross R.A. Association of vascular amyloid beta and cells of the mononuclear phagocyte system in hereditary cerebral hemorrhage with amyloidosis (Dutch) and Alzheimer disease. J. Neuropathol. Exp. Neurol. 56:1997;273-284.
30. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of NINCDS-ADRDA work group. Neurology. 34:1984;939-944.
31. Meda L., Baron P., Prat E., Scarpini E., Scarlato G., Cassatela M.A., Rossi F. Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with β-amyloid [25-35]. J. Neuroimmunol. 93:1999;45-52.
32. O'Mahony L., Holland J., Jackson J., Feighery C., Hennessy T.P., Mealy K. Quantitative intracellular cytokine measurement: age-related changes in proinflammatory cytokine production. Clin. Exp. Immunol. 113:1998;213-219.
33. O'Shea J.J., Ma A., Lipsky P. Cytokines and autoimmunity. Nat. Rev., Immunol. 2:2002;37-45.
34. Paganelli R., Di Iorio A., Patricelli L., Ripani F., Sparvieri E., Faricelli R., Iarlori C., Porreca E., Di Gioacchino M., Abate G. Proinflammatory cytokines in sera of elderly patients with dementia: levels in vascular injury are higher than those of mild-moderate Alzheimer's disease patients. Exp. Gerontol. 37:2002;257-263.
35. Perry R.T., Collins J.S., Wiener H., Acton R., Go R.C.P. The role of TNF and its receptors in Alzheimer's disease. Neurobiol. Aging. 22:2001;873-883.
36. Porrini A.M., De Luca G., Gambi D., Reder A.T. Effects of an anti-IL-10 monoclonal antibody on rIFNbeta-1b-mediated immune modulation. Relevance to multiple sclerosis. J. Neuroimmunol. 81:1998;109-115.
37. Rossi F., Bianchini E. Synergistic induction of nitric oxide by β-amyloid and cytokines in astrocytes. Biochem. Biophys. Res. Commun. 225:1996;474-478.
38. Rothwell N.J., Hopkins S.J. Cytokines and the nervous system: II. Actions and mechanisms of action. Trends Neurosci. 18:1995;130-136.
39. Sheng J.G., Ito K., Skinner R.D., Mrak R.E., Rovnaghi C.R., van Eldik L.J., Griffin W.S.T. In vivo, and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol. Aging. 17:1996;761-766.
40. Shibata N., Ohnuma T., Takahashi T., Baba H., Ishizuka T., Ohtsuka M., Ueki A., Nagao M., Arai H. Effect of IL-6 polymorphism on risk of Alzheimer disease: genotype-phenotype association study in Japanese cases. Am. J. Med. Genet. 114:2002;436-439.
41. Sredni-Kenigsbuch D. TH1/TH2 cytokines in the central nervous system. Int. J. Neurosci. 112:2002;665-703.
42. Szcepanik A.M., Funes S., Petko W., Ringheim G.E. IL-4, IL-10 and IL-13 modulate A-beta(1-42)-induced cytokine and chemokines production in primary murine microglia and a human cell line. J. Neuroimmunol. 113:2001;49-62.
43. Szczepanik A.M., Rampe D., Ringheim G.E. Amyloid-beta peptide fragment p3 and p4 induce pro-inflammatory cytokine and chemokine production in vitro and in vivo. J. Neurochem. 77:2001;304-317.
44. Tayebati S.K., Amenta F., Amici S., El-Assouad D., Gallai V., Ricci A., Parnetti L. Peripheral blood lymphocytes muscarinic cholinergic receptor subtypes in Alzheimer's disease: a marker of cholinergic dysfunction? J. Neuroimmunol. 121:2001;126-131.
45. te Velde A.A., Huijbens R.J., Heije K., de Vries J.E., Figdor C.G. Interleukin-4 (IL-4) inhibits secretion of IL-1beta, tumour necrosis factor alpha, and IL-6 by human monocytes. Blood. 76:1990;1392-1397.
46. Winblad B., Engedal K., Soininen H. A 1-year, randomized, placebo-controlled study of Donepezil in patients with mild to moderate AD. Neurology. 57:2001;489-495.
47. Yates S.L., Burgess L.H., Kocsis-Angle J., Antal J.M., Dority M.D., Embury P.B., Piotrkowski A.M., Brunden K.R. Amyloid beta and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia. J. Neurochem. 74:2000;1017-1025.